E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Alcohol-Induced Liver Decompensation (AILD) |
|
E.1.1.1 | Medical condition in easily understood language |
Alcohol-Induced Liver Decompensation (AILD) |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Metabolic Phenomena [G03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019755 |
E.1.2 | Term | Hepatitis chronic active |
E.1.2 | System Organ Class | 10019805 - Hepatobiliary disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to evaluate safety and efficacy of ELAD® with respect to overall survival (OS) of subjects with a clinical
diagnosis of alcohol-induced liver decompensation (AILD) through at
least Study Day 91, with follow-up Protocol VTL-308E providing
additional survival data up to a maximum of 5 years that will be
included, as available, through VTL-308 study termination (after the last
surviving enrolled subject completes Study Day 91). The primary
objective will be assessed using a Kaplan-Meier survival analysis of the
Intent-to-Treat (ITT) population utilizing a log-rank test. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to evaluate the proportion of survivors at Study Day 91 using a chi-squared test. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must meet ALL inclusion criteria to be eligible for the study:
1. Age ≥ 18;
2. Total bilirubin ≥16 mg/dL (≥273.6 μmol/L);
3. A clinical diagnosis of alcohol-induced liver decompensation (AILD),
based upon lab test or medical history or family interview with a causal
relationship and temporal association (6 weeks or less) of alcohol use
and hospital admission for this episode of AILD;
4. Maddrey score ≥32;
5. Subjects must have AILD that is severe acute alcoholic hepatitis(sAAH) diagnosed with either:
a. A confirmatory liver biopsy, OR
b. Two or more of the following:
i. Hepatomegaly,
ii. AST > ALT,
iii. Ascites,
iv. Leukocytosis (WBC count above lab normal at site);
Note: Subjects will be classified as either:
a. AILD that is sAAH with no underlying liver disease other than
alcoholic liver disease, OR
b. AILD that is sAAH with evidence of underlying liver disease other
than alcoholic liver disease which must be documented by:
i. Liver biopsy, AND/OR
ii. Laboratory findings, AND/OR
iii. Medical history;
6. Not eligible for liver transplant during this hospitalization;
7. Subject or legally-authorized representative must provide Informed
Consent;
8. Subject must be eligible for Standard of Care treatment as defined in
the protocol. |
|
E.4 | Principal exclusion criteria |
Subjects must NOT have any of the following exclusion criteria:
1. Age ≥50;
2. Platelet count <40,000/mm3;
3. International Normalization Ratio (INR) >2.5;
4. Serum Creatinine ≥1.3 mg/dL (≥115.04 μmol/L);
5. MELD score ≥30;
6. AST >500 IU/L;
7. Evidence of infection unresponsive to antibiotics (e.g. increased tissue involvement relative to initial diagnosis, clinical worsening of symptoms, etc.) indicated by any of the following:
a. Presence of sepsis or septic shock; OR
b. Positive blood cultures (bacteremia, fungemia) within 72 hours prior
to Randomization; OR
c. Presence of spontaneous bacterial peritonitis during the 2 days prior
to Randomization; OR
d. Clinical and radiological signs of pneumonia;
8. Evidence of reduction in total bilirubin of 20% or more in the previous 72 hours. Bilirubin measurements must be taken at least 12 hours after any procedure known to artificially alter serum bilirubin (e.g., administration of packed red blood cells, plasma exchange);
9. Evidence of hemodynamic instability as defined by the following:
a. Systolic blood pressure <90 mmHg with evidence of diminished
perfusion unresponsive to fluid resuscitation and/or low-dose pressor
support; OR
b. Mean arterial pressure (MAP) <60 mmHg with evidence of
diminished perfusion unresponsive to fluid resuscitation and/or low-dose pressor support; OR
c. Requirement for escalating doses of vasopressor support prior to
Screening; OR
d. Subject on vasopressors, including but not limited to those listed
below, at doses above the following at Screening or Randomization:
• Dobutamine: 5.0 μg/kg/min
• Dopamine: 2.0 μg/kg/min
• Norepinephrine: 0.02 μg/kg/min
• Phenylephrine: 1.0 μg/kg/min
• Vasopressin: 0.02 U/min
10. Evidence of active bleeding, major hemorrhage defined as requiring
≥2 units packed red blood cells to maintain a stable haemoglobin
occurring within 48 hours prior to Randomization, or with banding of
gastroesophageal varices during the 7 days immediately preceding
screening;
11. Clinical evidence of liver size reduction due to cirrhosis [liver size of
the craniocaudal diameter (sagittal view) <10 cm when measured on the mid clavicular line (or equivalent measurement) by ultrasound, or liver volume <1200 cc as determined by CT or MRI], unless Investigator
interpretation of the clinical evidence indicates liver size of <10 cm or
volume <1200 cc is not considered reduced for the individual subject,
and Sponsor agrees;
12. Occlusive portal vein thrombosis impairing hepatopetal flow, or
evidence of bile duct obstruction;
13. Evidence by physical exam, history, or laboratory evaluation, of
significant concomitant disease with a life expectancy of less than 3
months, including, but not limited to:
a. Severe acute or chronic cardiovascular, central nervous system, or
pulmonary disease;
b. Cancer that has metastasized or has not yet been treated;
c. Severe metabolic abnormalities that have not been corrected;
14. Subject has chronic end-stage renal disease requiring chronic
hemodialysis for more than 8 weeks (not classified as hepatorenal
syndrome);
15. Subject ventilated or intubated;
16. Subject on hemodialysis;
17. Subject has liver disease related to homozygous hemachromotosis,
Wilson's disease, has non alcoholic fatty liver disease, or Budd-Chiari
Syndrome;
18. Serological evidence (including viral titers) of active viral hepatitis A,
B or C infection. If the investigator suspects that the subject may be at
risk for viral hepatitis A, B or C, and no serology is available, then
serologies MUST be obtained prior to Randomization, as a positive
serology would be exclusionary;
19. Pregnancy as determined by serum β-human chorionic gonadotropin (HCG) results, or subjects of child-bearing potential not willing to use effective means of contraception, without history of medical or surgical sterilization;
20. Participation in another investigational drug, biologic, or device
study within one month of enrolment, except for observational studies
(the observational study setting should not affect the safety and/or
efficacy of the VTL-308 clinical trial);
21. Previous liver transplant;
22. Previous enrolment in the treatment phase of another ELAD trial;
23. Have a Do Not Resuscitate or a Do Not Intubate (DNR/DNI) directive
(or such local equivalent) or any other Advanced Directive limiting
Standard of Care in place (the DNR/DNI criterion is not applicable in
Europe);
24. Refusal to participate in the VTL-308E follow-up study;
25. Inability to provide an address for home visits. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall Survival (OS) will be assessed using a Kaplan-Meier survival
analysis of the intent-to-treat (ITT) population utilizing a log-rank test,
with follow-up Protocol VTL-308E providing additional survival data up
to a maximum of 5 years that will be included, as available, through VTL-308 study termination. Model-based estimates and confidence limits will be calculated for median survival by treatment group and the hazard ratio and its confidence limits. This analysis will also be carried out on the mITT, Per-Protocol (PP) and Safety populations as sensitivity analyses. Two-tailed alpha for the log-rank test will be set at 0.05. The statistical analysis plan will outline the methods used to account for missing data in this and all other analyses.
The statistical analysis plan will also evaluate differences in standard of
care between the groups that may affect subject outcome, such as
differences in the administration of steroid therapy, and define analytical strategies to deal with those differences should they arise. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After all enrolled subjects either complete Study Day 91, are lost to
follow up or withdraw consent, or die before that Study Day. |
|
E.5.2 | Secondary end point(s) |
A chi-square test will be used to evaluate the proportion of subjects who survived at End of Study Day 91 based on the ITT population. Two-tailed alpha will be set at 0.05. This analysis will also be carried out on the mITT, PP and Safety populations as sensitivity analyses. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Standard of care treatment for AILD (as defined in the protocol) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
Germany |
Ireland |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |